PMID- 30332670
OWN - NLM
STAT- MEDLINE
DCOM- 20200427
LR  - 20220409
IS  - 1423-0356 (Electronic)
IS  - 0025-7931 (Linking)
VI  - 97
IP  - 3
DP  - 2019
TI  - Efficacy and Safety of Pirfenidone in Advanced Idiopathic Pulmonary Fibrosis.
PG  - 242-251
LID - 10.1159/000492937 [doi]
AB  - BACKGROUND: Although phase 3 trials showed significant efficacy and acceptable 
      safety profiles for pirfenidone in mild-to-moderate idiopathic pulmonary fibrosis 
      (IPF), data on advanced IPF are limited. OBJECTIVES: The study aimed to evaluate 
      the efficacy and safety of pirfenidone in advanced IPF patients. METHODS: The 
      clinical data of 138 IPF patients (advanced group: 27%) treated with pirfenidone 
      were retrospectively reviewed and compared between advanced and non-advanced 
      groups. Advanced IPF was defined as (1) forced vital capacity (FVC) < 50% 
      predicted or (2) diffusing capacity for carbon monoxide < 30% predicted. RESULTS: 
      The mean treatment duration was 51.3 weeks, and lung function analysis was 
      performed in 81 patients (17 in the advanced group). Changes in FVC and total 
      lung capacity (TLC) were significantly reduced at 6 months after treatment in 
      both the advanced (DeltaFVC [6 months]: -6.3 [before] vs. 0.7% predicted [after]; 
      DeltaTLC: -5.3 vs. 0.8) and non-advanced (DeltaFVC: -3.4 vs. 0.5; DeltaTLC: -3.1 vs. -0.9) 
      groups. The rate of decline in FVC and TLC was significant before treatment, but 
      not after treatment in the advanced (FVC: -1.27 [before] vs. 0.21% 
      predicted/month [after]; TLC: -0.89 vs. -0.15) and non-advanced (FVC: -0.60 vs. 
      -0.20; TLC: -0.54 vs. -0.17) groups. The advanced group showed a similar rate of 
      adverse events (AEs) (78.4 vs. 88.1%, p = 0.270), but more serious AEs (40.5 vs. 
      10.9%, p < 0.001) including death (24.3 vs. 5.0%, p = 0.002). CONCLUSIONS: In 
      advanced IPF, pirfenidone showed similar efficacy and safety to non-advanced IPF 
      except for serious AEs, which may be due to the advanced status itself.
CI  - (c) 2018 S. Karger AG, Basel.
FAU - Yoon, Hee-Young
AU  - Yoon HY
FAU - Kim, Dong Soon
AU  - Kim DS
FAU - Song, Jin Woo
AU  - Song JW
LA  - eng
PT  - Journal Article
DEP - 20181017
PL  - Switzerland
TA  - Respiration
JT  - Respiration; international review of thoracic diseases
JID - 0137356
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Pyridones)
RN  - D7NLD2JX7U (pirfenidone)
SB  - IM
CIN - Respiration. 2019;97(3):202-204. PMID: 30453286
MH  - Aged
MH  - Anti-Inflammatory Agents, Non-Steroidal/administration & dosage
MH  - Disease Progression
MH  - Dose-Response Relationship, Drug
MH  - Female
MH  - Follow-Up Studies
MH  - Humans
MH  - Idiopathic Pulmonary Fibrosis/diagnosis/*drug therapy/physiopathology
MH  - Male
MH  - Plethysmography
MH  - Pyridones/*administration & dosage
MH  - Retrospective Studies
MH  - Total Lung Capacity/*physiology
MH  - Treatment Outcome
OTO - NOTNLM
OT  - Adverse effects
OT  - Idiopathic pulmonary fibrosis
OT  - Pirfenidone
OT  - Respiratory function test
OT  - Treatment outcome
EDAT- 2018/10/18 06:00
MHDA- 2020/04/28 06:00
CRDT- 2018/10/18 06:00
PHST- 2018/02/07 00:00 [received]
PHST- 2018/08/14 00:00 [accepted]
PHST- 2018/10/18 06:00 [pubmed]
PHST- 2020/04/28 06:00 [medline]
PHST- 2018/10/18 06:00 [entrez]
AID - 000492937 [pii]
AID - 10.1159/000492937 [doi]
PST - ppublish
SO  - Respiration. 2019;97(3):242-251. doi: 10.1159/000492937. Epub 2018 Oct 17.